(EMAILWIRE.COM, September 15, 2018 ) Factors such as increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies propel the growth of the market. Some of the opportunities for the market are low income countries like India and Africa lacking access to basic healthcare and increasing risk of pandemic and communicable diseases. However, in spite of innovative technologies in the market, developing stable and authentic cell lines remains a major challenge of this market.

The cell line development market, by type of cell lines is segmented into primary cell lines, continuous cell lines, hybridomas, and recombinant cell lines. On the basis of source, the market is segmented into mammalians, insects, and amphibians. On the basis of applications, the market is segmented into bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery.

The global cell line development market is expected to reach $3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.

Get More Details: https://www.marketsandmarkets.com/Market-Reports/cell-line-development-market-152900899.html 

Some of the major players in the global market include American Type Culture Collection (ATCC) (U.S.), Lonza Group AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.K.), Sigma Aldrich Corporation (U.S.), Selexis SA (Switzerland), European Collection of Cell Cultures (ECACC) (U.K.), Corning, Inc. (U.S.), Wuxi App Tec, Inc. (China), and Sartorious AG (Germany).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
newsletter@marketsandmarkets.com